VYNE Therapeutics (NASDAQ:VYNE) Releases Quarterly Earnings Results, Beats Estimates By $0.10 EPS

VYNE Therapeutics (NASDAQ:VYNE) posted its earnings results on Friday. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.10, FiscalAI reports. The company had revenue of $0.09 million during the quarter, compared to analyst estimates of $0.20 million. VYNE Therapeutics had a negative return on equity of 74.86% and a negative net margin of 4,646.14%.

VYNE Therapeutics Stock Performance

NASDAQ VYNE traded down $0.00 during trading on Friday, hitting $0.67. The stock had a trading volume of 106,393 shares, compared to its average volume of 292,626. The company has a market capitalization of $22.32 million, a PE ratio of -0.86 and a beta of 2.00. The company’s 50-day moving average price is $0.62 and its two-hundred day moving average price is $0.54. VYNE Therapeutics has a 12 month low of $0.28 and a 12 month high of $1.96.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of VYNE Therapeutics in a research report on Monday, May 4th. Wall Street Zen upgraded VYNE Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, February 2nd. Three research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Reduce”.

Institutional Investors Weigh In On VYNE Therapeutics

Several institutional investors have recently bought and sold shares of VYNE. Anson Funds Management LP bought a new stake in VYNE Therapeutics in the 4th quarter valued at approximately $739,000. Nantahala Capital Management LLC bought a new stake in shares of VYNE Therapeutics during the 4th quarter worth approximately $580,000. KVP Capital Advisors LP bought a new stake in shares of VYNE Therapeutics during the 4th quarter worth approximately $290,000. Shay Capital LLC bought a new stake in shares of VYNE Therapeutics during the 3rd quarter worth approximately $165,000. Finally, Adage Capital Partners GP L.L.C. raised its stake in shares of VYNE Therapeutics by 87.2% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 644,134 shares of the company’s stock worth $1,063,000 after purchasing an additional 300,000 shares in the last quarter. Institutional investors own 83.78% of the company’s stock.

About VYNE Therapeutics

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.